Elevated hs-CRP associates with airflow limitation and PRISm in 335 adult liver transplant recipients.
The Danish Comorbidity in Liver Transplant Recipients (DACOLT) study included 335 adult liver transplant recipients. The primary exposure was elevated inflammatory markers, defined as hs-CRP >3 mg/L, compared to hs-CRP ≤3 mg/L. Outcomes included airflow limitation, PRISm, FEV1, and FVC. Follow-up duration was not reported.
Results indicated that elevated hs-CRP was associated with increased odds of PRISm (aOR 2.08; 95% CI: 1.1; 3.9, p=0.02) and lower FEV1 (-209 mL; 95% CI -340; -77 mL, p=0.02). The prevalence of airflow limitation was 11.6%, and the prevalence of PRISm was 24.5%. Median FEV1 was 2790 mL (IQR 2230–3505 mL) and median FVC was 3680 mL (IQR 2980–3755 mL).
Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported. Results were adjusted for age and sex. A key limitation is that no studies have investigated this association in liver transplant recipients prior to this work. Because the study is observational, causality cannot be established, and clinical significance of these surrogate markers without clinical outcome correlation should not be assumed.